IS2849B - Notkun á írbesartani til framleiðslunnar á lyfjum sem eru notuð til að fyrirbyggja eða meðhöndla lungnaháþrýsting - Google Patents

Notkun á írbesartani til framleiðslunnar á lyfjum sem eru notuð til að fyrirbyggja eða meðhöndla lungnaháþrýsting

Info

Publication number
IS2849B
IS2849B IS7200A IS7200A IS2849B IS 2849 B IS2849 B IS 2849B IS 7200 A IS7200 A IS 7200A IS 7200 A IS7200 A IS 7200A IS 2849 B IS2849 B IS 2849B
Authority
IS
Iceland
Prior art keywords
irbesartan
manufacture
prevent
pulmonary hypertension
drugs used
Prior art date
Application number
IS7200A
Other languages
English (en)
Other versions
IS7200A (is
Inventor
Sylvie Cosnier-Pucheu
Dino Nisato
Alain Roccon
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of IS7200A publication Critical patent/IS7200A/is
Publication of IS2849B publication Critical patent/IS2849B/is

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10Antioedematous agents; Diuretics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
IS7200A 2001-10-26 2004-03-29 Notkun á írbesartani til framleiðslunnar á lyfjum sem eru notuð til að fyrirbyggja eða meðhöndla lungnaháþrýsting IS2849B (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0113936A FR2831446B1 (fr) 2001-10-26 2001-10-26 Utilisation de l'irbesartan pour la preparation de medicaments utiles pour la prevention ou le traitement de l'hypertension pulmonaire
PCT/FR2002/003439 WO2003035062A1 (fr) 2001-10-26 2002-10-09 Utilisation de l'irbesartan pour la preparation de medicaments utiles pour la prevention ou le traitement de l'hypertension pulmonaire

Publications (2)

Publication Number Publication Date
IS7200A IS7200A (is) 2004-03-29
IS2849B true IS2849B (is) 2013-09-15

Family

ID=8868812

Family Applications (1)

Application Number Title Priority Date Filing Date
IS7200A IS2849B (is) 2001-10-26 2004-03-29 Notkun á írbesartani til framleiðslunnar á lyfjum sem eru notuð til að fyrirbyggja eða meðhöndla lungnaháþrýsting

Country Status (24)

Country Link
US (2) US20040242567A1 (is)
EP (1) EP1441723B1 (is)
JP (1) JP4542777B2 (is)
CN (1) CN100418526C (is)
AT (1) ATE361071T1 (is)
AU (1) AU2002350832B2 (is)
BR (1) BR0213479A (is)
CA (1) CA2461625C (is)
CY (1) CY1106746T1 (is)
DE (1) DE60219940T2 (is)
DK (1) DK1441723T3 (is)
EA (1) EA007952B1 (is)
ES (1) ES2286304T3 (is)
FR (1) FR2831446B1 (is)
HU (1) HUP0401633A3 (is)
IL (2) IL161116A0 (is)
IS (1) IS2849B (is)
MX (1) MXPA04003910A (is)
NO (1) NO332313B1 (is)
NZ (1) NZ532130A (is)
PL (1) PL209263B1 (is)
PT (1) PT1441723E (is)
WO (1) WO2003035062A1 (is)
ZA (1) ZA200402696B (is)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9808471B2 (en) 2003-04-16 2017-11-07 Mylan Specialty Lp Nasal pharmaceutical formulations and methods of using the same
US8912174B2 (en) 2003-04-16 2014-12-16 Mylan Pharmaceuticals Inc. Formulations and methods for treating rhinosinusitis
US7811606B2 (en) 2003-04-16 2010-10-12 Dey, L.P. Nasal pharmaceutical formulations and methods of using the same
US20040265238A1 (en) * 2003-06-27 2004-12-30 Imtiaz Chaudry Inhalable formulations for treating pulmonary hypertension and methods of using same
TR200301553A1 (tr) * 2003-09-18 2005-10-21 Nobel �La� Sanay�� Ve T�Caret A.�. İrbesartan etken maddesi içeren yeni oral farmasötik formülasyonlar
CA2568640C (en) 2004-06-04 2011-08-09 Teva Pharmaceutical Industries Ltd. Pharmaceutical composition containing irbesartan
WO2006067601A1 (en) * 2004-12-23 2006-06-29 Ranbaxy Laboratories Limited Oral pharmaceutical compositions of irbesartan and hydrochlorothiazide and processes for their preparation
CN100367959C (zh) * 2006-08-29 2008-02-13 陈俊云 一种含有依贝沙坦的药物
GB0617171D0 (en) * 2006-08-31 2006-10-11 Generics Uk Ltd Novel compositions and methods
US20240173302A1 (en) * 2021-03-23 2024-05-30 Dimerix Bioscience Pty Ltd Treatment of inflammatory diseases

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5258510A (en) * 1989-10-20 1993-11-02 Otsuka Pharma Co Ltd Benzoheterocyclic compounds
US5270317A (en) * 1990-03-20 1993-12-14 Elf Sanofi N-substituted heterocyclic derivatives, their preparation and the pharmaceutical compositions in which they are present
NZ237476A (en) * 1990-03-20 1994-01-26 Sanofi Sa N-substituted heterocyclic compounds and pharmaceutical compositions.
RU2086544C1 (ru) * 1991-06-13 1997-08-10 Хоффманн-Ля Рош АГ Бензолсульфонамидные производные пиримидина или их соли, фармацевтическая композиция для лечения заболеваний, связанных с активностью эндотелина
US5292741A (en) * 1992-08-18 1994-03-08 Merck & Co., Inc. Macrocycles incorporating quinazolinones
US20020068740A1 (en) 1999-12-07 2002-06-06 Mylari Banavara L. Combination of aldose reductase inhibitors and antihypertensive agents for the treatment of diabetic complications

Also Published As

Publication number Publication date
ES2286304T3 (es) 2007-12-01
EP1441723B1 (fr) 2007-05-02
NO332313B1 (no) 2012-08-27
US8088827B2 (en) 2012-01-03
CA2461625A1 (en) 2003-05-01
DK1441723T3 (da) 2007-09-10
EA200400438A1 (ru) 2004-10-28
IS7200A (is) 2004-03-29
JP4542777B2 (ja) 2010-09-15
PT1441723E (pt) 2007-07-26
PL368737A1 (en) 2005-04-04
ATE361071T1 (de) 2007-05-15
DE60219940D1 (de) 2007-06-14
NO20041732L (no) 2004-07-23
NZ532130A (en) 2006-10-27
WO2003035062A1 (fr) 2003-05-01
US20090247510A1 (en) 2009-10-01
AU2002350832B2 (en) 2006-11-30
IL161116A (en) 2010-12-30
EP1441723A1 (fr) 2004-08-04
MXPA04003910A (es) 2004-07-23
PL209263B1 (pl) 2011-08-31
CY1106746T1 (el) 2012-05-23
CN1610548A (zh) 2005-04-27
HUP0401633A2 (hu) 2004-12-28
JP2005506369A (ja) 2005-03-03
FR2831446B1 (fr) 2004-03-05
HUP0401633A3 (en) 2009-06-29
EA007952B1 (ru) 2007-02-27
CN100418526C (zh) 2008-09-17
FR2831446A1 (fr) 2003-05-02
US20040242567A1 (en) 2004-12-02
ZA200402696B (en) 2005-06-29
IL161116A0 (en) 2004-08-31
CA2461625C (en) 2011-07-05
DE60219940T2 (de) 2008-01-17
BR0213479A (pt) 2004-11-03

Similar Documents

Publication Publication Date Title
MX2007002470A (es) Fenilaminotiazoles sustituidos y su uso.
TNSN05045A1 (en) Indole or benzimidazole derivatives for modulating ikappab kinase
NO20053855L (no) 1-fenylalkankarboksylsyrederivater til behandling av neurodegenerative sykdommer.
MY145077A (en) Pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
NO20055863L (no) W-karboksyarylsubstituerte difenylureaforbindelser som raf-kinaseinhibitorer
PL372809A1 (en) Substituted 1,3-diphenylprop-2-en-1-one derivatives and preparation and uses thereof
NO20055563L (no) Midler for behandlingen av lavere abdominale lidelser
MY141528A (en) Anilinopyrazole derivatives useful for the treatment of diabetes
IS2849B (is) Notkun á írbesartani til framleiðslunnar á lyfjum sem eru notuð til að fyrirbyggja eða meðhöndla lungnaháþrýsting
NO20076405L (no) Anvendelse av 24-nor-UDCA
PL1843771T3 (pl) Zastosowanie pirymidyloaminobenzamidów do leczenia chorób odpowiadających na modulację aktywności kinazy Tie-2
AU2002350832A1 (en) Use of irbesartan for the preparation of medicaments that are used to prevent or treat pulmonary hypertension
DE602004019541D1 (de) Cycloalkyläbü kondensierte indole
NO20014081L (no) Anvendelse av tianeptin i produksjonen av medikamenter til behandling av nevrodegenerative patologier
WO2004055001A3 (en) Rabeprazole calcium
UY26930A1 (es) Amidas de ácido fenilciclohexanocarboxílico sustituido y su uso
IS7418A (is) Sítalópram til að meðhöndla hækkaðan blóðþrýsting
SE0001631D0 (sv) New use
AP1731A (en) Use of an inhibitor of the renin-angiotensin system for the manufacture of a medicament or prevention of lipodystrophy syndorme.
WO2004103291A3 (en) Extended release compositions of proton pump inhibitor
WO2003064394A8 (de) 5-ring heterozyklen zur verwendung als antiviral mittel
SI1441723T1 (sl) Uporaba irbesartana za preprečevanje ali zdravljenje pljučne hipertenzije
UA87851C2 (ru) Производные пирролотриазина, применимые для лечения гиперпролиферативных нарушений и заболеваний, связанных с ангиогенезом
NO20051879L (no) Anvendelse av proteintyrosinfosfataseinhibitorer til forhindring og/eller behandling av kreft
BG105763A (en) Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors